1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Ablation Equipments Overview

3 Products under Development
3.1 Ablation Equipments - Pipeline Products by Stage of Development
3.2 Ablation Equipments - Pipeline Products by Territory
3.3 Ablation Equipments - Pipeline Products by Regulatory Path
3.4 Ablation Equipments - Pipeline Products by Estimated Approval Date
3.5 Ablation Equipments - Ongoing Clinical Trials

4 Ablation Equipments - Pipeline Products under Development by Companies
4.1 Ablation Equipments Companies - Pipeline Products by Stage of Development
4.2 Ablation Equipments - Pipeline Products by Stage of Development

5 Ablation Equipments Companies and Product Overview
5.1 AngioDynamics Inc Company Overview
5.1.1 AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.2 Avenda Health Inc Company Overview
5.2.1 Avenda Health Inc Pipeline Products & Ongoing Clinical Trials Overview
5.3 CPSI Biotech Company Overview
5.3.1 CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview
5.4 Creo Medical Ltd Company Overview
5.4.1 Creo Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.5 Deneb Medical SL Company Overview
5.5.1 Deneb Medical SL Pipeline Products & Ongoing Clinical Trials Overview

6 Ablation Equipments- Recent Developments
6.1 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019
6.2 Nov 15, 2019: Fractyl announces new data from Revita-1 clinical study showing durable benefits after a single treatment through two years of follow up
6.3 Nov 14, 2019: Medtronic highlights leadership in inclusion, diversity, and equity in 2019 integrated performance report
6.4 Nov 08, 2019: Fractyl announces Revita-2 data showing Revita DMR provides statistically significant improvements in blood glucose and liver fat in type 2 diabetes with and without NAFLD
6.5 Nov 06, 2019: Olympus unveils corporate strategy

7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer

List of Tables
Table 1: Ablation Equipments - Pipeline Products by Stage of Development
Table 2: Ablation Equipments - Pipeline Products by Territory
Table 3: Ablation Equipments - Pipeline Products by Regulatory Path
Table 4: Ablation Equipments - Pipeline Products by Estimated Approval Date
Table 5: Ablation Equipments - Ongoing Clinical Trials
Table 6: Ablation Equipments Companies - Pipeline Products by Stage of Development
Table 7: Ablation Equipments - Pipeline Products by Stage of Development
Table 8: AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Status
Table 10: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Description
Table 11: Nanoknife System - Bladder Cancer - Product Status
Table 12: Nanoknife System - Bladder Cancer - Product Description
Table 13: NanoKnife System - Cervical Cancer - Product Status
Table 14: NanoKnife System - Cervical Cancer - Product Description
Table 15: NanoKnife System - Head And Neck Cancer - Product Status
Table 16: NanoKnife System - Head And Neck Cancer - Product Description
Table 17: NanoKnife System - Lung Cancer - Product Status
Table 18: NanoKnife System - Lung Cancer - Product Description
Table 19: Nanoknife System - Metastatic Lymph Nodes - Product Status
Table 20: Nanoknife System - Metastatic Lymph Nodes - Product Description
Table 21: NanoKnife System - Prostate Cancer - Product Status
Table 22: NanoKnife System - Prostate Cancer - Product Description
Table 23: NanoKnife System - Rectal Cancer - Product Status
Table 24: NanoKnife System - Rectal Cancer - Product Description
Table 25: Nanoknife System - Renal Pelvis Urothelial Neoplasms - Product Status
Table 26: Nanoknife System - Renal Pelvis Urothelial Neoplasms - Product Description
Table 27: NanoKnife System - Stage III Pancreatic Cancer - Product Status
Table 28: NanoKnife System - Stage III Pancreatic Cancer - Product Description
Table 29: Nanoknife System - Stomach Neoplasm - Product Status
Table 30: Nanoknife System - Stomach Neoplasm - Product Description
Table 31: AngioDynamics Inc - Ongoing Clinical Trials Overview
Table 32: NanoKnife System - Prostate Cancer - A Pilot Study in Human Subjects Evaluating the Use of the NanoKnife System for Ablation of Prostate Cancer Tissue in a Low and Intermediate Risk Patient Population
Table 33: NanoKnife System - Prostate Cancer - Efficacy and Safety Assessment of Nanoknife (AngyoDynamics, USA) for Irreversible Electroporation (IRE) of Localized Prostate Cancer
Table 34: NanoKnife System - Prostate Cancer - Examination of Focal Therapies - MR.pdfI-Fusion, HIFU, NanoKnife and Cryotherapy
Table 35: NanoKnife System - Prostate Cancer - Focal Irreversible Electroporation as Salvage Treatment in Radio-recurrent Prostate Cancer: A Prospective Multicenter Pilot Study
Table 36: NanoKnife System - Prostate Cancer - Irreversible Electroporation (IRE) for Unresectable Prostatic Neoplasms: Phase I and Phase II Clinical Trial
Table 37: NanoKnife System - Prostate Cancer - Multi-center Randomized Clinical Two Arm Intervention Study Evaluating Irreversible Electroporation for the Ablation of Localized Prostate Cancer
Table 38: NanoKnife System - Prostate Cancer - Registry of Irreversible Electroporation for the Ablation of Prostate Cancer with Use of Nanoknife Device; A Multi-center, International Registry to Evaluate the Treatment of Prostate Cancer in Terms of Recurrence, Functional Outcomes and Safety
Table 39: NanoKnife System - Stage III Pancreatic Cancer - A Clinical Research about Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer
Table 40: NanoKnife System - Stage III Pancreatic Cancer - A Pilot Study of Irreversible Electroporation for the Treatment of Upfront Resectable Pancreatic Cancer in the Head of the Pancreas
Table 41: NanoKnife System - Stage III Pancreatic Cancer - A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma
Table 42: NanoKnife System - Stage III Pancreatic Cancer - Ablation of Unresectable Locally Advanced Pancreatic Cancer with Nanoknife Irreversible Electroporation (IRE) System: Response and Tolerability
Table 43: NanoKnife System - Stage III Pancreatic Cancer - Assessing Optimal Treatment Settings for the Ablation of Locally Advanced Pancreatic Cancer with CT-guided Percutaneous Irreversible Electroporation (ANTILOPE): A Randomized Feasibility Study
Table 44: NanoKnife System - Stage III Pancreatic Cancer - Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival after Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation: CROSSFIRE Trial
Table 45: NanoKnife System - Stage III Pancreatic Cancer - Evaluation of the Short and Intermediate Term Outcomes of Ablation of Locally Advanced Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System - A Prospective Study
Table 46: NanoKnife System - Stage III Pancreatic Cancer - Impact of Irreversible Electroporation on Quality of Life for Patients with Locally Advanced Pancreatic Cancer
Table 47: NanoKnife System - Stage III Pancreatic Cancer - Interest of Irreversible Electroporation in the Treatment of Pancreatic Adenocarcinoma
Table 48: NanoKnife System - Stage III Pancreatic Cancer - IRE: Anti-tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer
Table 49: NanoKnife System - Stage III Pancreatic Cancer - Irreversible Electroporation for Locally Advanced Pancreatic Ductal Adenocarcinoma (LEAP TRIAL): A Phase I/II Prospective Trial
Table 50: NanoKnife System - Stage III Pancreatic Cancer - Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma
Table 51: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Unresectable Hepatic Carcinoma Close to the Gallbladder
Table 52: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers
Table 53: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Colorectal Metastatic Liver Disease: Efficacy of Irreversible Electroporation (IRE) - A Phase II Clinical Trial: COLDFIRE-2 Study
Table 54: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Comparison Percutaneous Cryosurgery and Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome
Table 55: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE)
Table 56: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Irreversible Electroporation (IRE) for Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial
Table 57: Nanoknife System - Renal Pelvis Urothelial Neoplasms - Irreversible Electroporation (IRE) for Unresectable Renal Pelvic and Ureteral Neoplasms: Phase I and Phase II Clinical Trial
Table 58: Nanoknife System - Metastatic Lymph Nodes - Irreversible Electroporation (IRE) for Unresectable Lymph Node Metastases: Phase I and Phase II Clinical Trial
Table 59: NanoKnife System - Lung Cancer - Irreversible Electroporation (IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency: Phase I and Phase II Clinical Trial
Table 60: Nanoknife System - Stomach Neoplasm - Irreversible Electroporation (IRE) for Unresectable Stomach Neoplasms: Phase I and Phase II Clinical Trial

List of Figures
Figure 1: Ablation Equipments - Pipeline Products by Stage of Development
Figure 2: Ablation Equipments - Pipeline Products by Territory
Figure 3: Ablation Equipments - Pipeline Products by Regulatory Path
Figure 4: Ablation Equipments - Pipeline Products by Estimated Approval Date
Figure 5: Ablation Equipments - Ongoing Clinical Trials

Companies Mentioned
- AngioDynamics Inc
- Avenda Health Inc
- CPSI Biotech
- Creo Medical Ltd
- Deneb Medical SL
- Elesta srl
- Ethicon US LLC
- Eximo Medical Ltd
- ExpandoHeat LLC
- Fractyl Laboratories Inc
- Harmonic Medical Inc
- HEPTA Medical SASU
- HistoSonics Inc
- Hospital for Special Surgery
- Integra LifeSciences Holdings Corp
- Intratherm LLC (Inactive)
- Massachusetts Institute of Technology
- Medtronic plc
- Memorial Sloan Kettering Cancer Center
- Mirabilis Medical Inc
- ProstaCare Pty Ltd
- Pulse Biosciences Inc
- Sabanci University Nanotechnology Research and Application Center
- Southern Illinois University Carbondale
- Thermedical Inc
- TransEnterix Inc
- University of California San Francisco
- University of Texas at Austin
- University of Wisconsin-Stout
- Verix Health